Phase 1 Repeat Dosing with BIVV001: The First Investigational Factor VIII Product to Break through the Von Willebrand Factor-Imposed Half-Life Ceiling

Category Primary study
JournalBlood
Year 2019
This article has no abstract
Epistemonikos ID: ea88d729b11e797f7158999b1c2d0b26606a3c14
First added on: Feb 11, 2025